Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Hepatitis c and lymphoma.

F Silvestri1, A Sperotto, R Fanin

  • 1Division of Hematology, University Hospital, 33100 Udine, Italy. Ematologia@drmm.uniud.it

Current Oncology Reports
|December 21, 2000
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

CPX-351: From preclinical studies to future directions.

Current opinion in pharmacology·2026
Same author

<i>Escherichia coli</i> producing AmpC DHA-1 bacteraemia in neutropenic leukemic patient: continuous infusion ceftazidime/avibactam as a carbapenem sparing regimen.

JAC-antimicrobial resistance·2025
Same author

A case of acute macular neuroretinopathy as atipycal ICANS manifestation after CAR-T cell infusion.

Leukemia & lymphoma·2024
Same author

Challenges in chimeric antigen receptor-T cell product administration in a high tumor-burden elderly patient with mantle-cell lymphoma.

Annals of hematology·2024
Same author

Effects of Fitlight training on cognitive-motor performance in élite judo athletes.

Heliyon·2024
Same author

RECURRENT LENTIGO MALIGNA: CONSERVATIVE CONTINUOUS TREATMENT WITH IMIQUIMOD OR REPEATED SURGERY? A LONG-TERM FOLLOW-UP DERMOSCOPIC CASE STUDY.

Experimental oncology·2023
Same journal

Revisiting the Immunological Landscape of Locoregional Therapies for Gastrointestinal Cancers: A Shift Toward Interventional Immuno-Oncology.

Current oncology reports·2026
Same journal

Anti-PD-1 Combinations: Triplets and Beyond.

Current oncology reports·2026
Same journal

Sacituzumab Tirumotecan Across Gynecologic Malignancies: One Target, Multiple Diseases.

Current oncology reports·2026
Same journal

Clusterin in Head and Neck Squamous Cell Carcinoma: Diagnostic, Prognostic, and Therapeutic Implications.

Current oncology reports·2026
Same journal

Cardiac Risk Without a Roadmap: Lack of Evidence-Based Guidance for Cardiovascular Toxicity of T-Cell Redirecting Therapies.

Current oncology reports·2026
Same journal

Current Understanding of CHIP's Immunobiological Footprint with A Focus on Gastrointestinal Disorders: A Review of the Literature.

Current oncology reports·2026
See all related articles

Hepatitis C virus (HCV) may contribute to certain B-cell non-Hodgkin

Area of Science:

  • Oncology
  • Virology
  • Immunology

Background:

  • Hepatitis C virus (HCV) infection is a global health concern.
  • Non-Hodgkin's lymphoma (NHL) encompasses various B-cell malignancies.
  • The potential link between viral infections and lymphomagenesis is an area of active research.

Purpose of the Study:

  • To review epidemiologic and experimental evidence linking HCV to specific B-cell non-Hodgkin's lymphoma subtypes.
  • To assess the safety of chemotherapy in hematologic malignancy patients with concurrent HCV infection.

Main Methods:

  • Systematic review of published epidemiologic studies.
  • Analysis of experimental data investigating the role of HCV in lymphoma development.
  • Evaluation of clinical data on chemotherapy outcomes in HCV-infected patients with hematologic malignancies.

Related Experiment Videos

Main Results:

  • Epidemiologic data suggest HCV involvement in the pathogenesis of certain B-cell NHL histotypes, including immunocytoma and lymphomas of the liver and salivary glands.
  • Experimental findings provide further support for the proposed pathogenetic link.
  • Patients with hematologic malignancies, including those with HCV infection, can be treated safely with standard and high-dose chemotherapy.

Conclusions:

  • HCV is implicated in the development of specific B-cell non-Hodgkin's lymphomas.
  • Chemotherapy is a safe and effective treatment option for hematologic malignancies, even in the presence of HCV infection.